Amivantamab + Lazertinib in 1st line Advanced EGFR + NSCLC - Mariposa
Update: 2025-06-02
Description
In this episode of MedOncNow, Dr. Kevin Jao discusses Amivantamab + Lazertinib in the first-line treatment of EGFR-mutated NSCLC and how it fits into the treatment landscape. This is timely, as Johnson & Johnson has a time-limited access program to Ami-Laz for EGFR-mutated NSCLC, as per the Mariposa Regimen.
More information in episodes 2 and 3.
Proudly partnering with Oncology Education for the 2025 season.
MedOncNow has been made possible by the generous unrestricted support of BMS, Eisai, Johnson and Jonhson, Merck, Pfizer and Roche Canada.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
